U.S. Healthtech Stock News

The Boards of Directors of Adams Diversified Equity Fund and Adams Natural Resources Fund recently elected Dr. Steven G. Chambers as an independent director, adding deep experience in educational technology and artificial intelligence to the Funds’ governance. This appointment underscores how a traditional closed-end equity fund is actively bringing AI and technology expertise into its oversight structure, reflecting the growing role of advanced analytics in asset management. We’ll now...

Cohen & Steers has already moved to convert its actively managed Future of Energy mutual fund into an exchange-traded fund, aligning the product with the ETF structure favored by many investors. This shift underscores how even historically mutual-fund-focused managers are repositioning their product lineups as mutual-fund-to-ETF conversions reached a record level in 2025. Next, we’ll examine how converting the Future of Energy Fund into an ETF could influence Cohen & Steers’ active ETF...

In recent days, Newmont has drawn attention as analysts highlighted stronger earnings expectations, firmer demand for precious metals amid geopolitical uncertainty, and the company’s upcoming February 19 earnings report as a key moment to gauge its exposure to higher gold and silver prices. An interesting angle is Newmont’s growing role in income-focused portfolios, with its inclusion in a high-dividend ETF and a relatively conservative payout ratio supporting perceptions of dividend...

10x Genomics FY 2025 earnings snapshot 10x Genomics (TXG) closed FY 2025 with Q4 revenue of US$166.0 million and a basic EPS loss of US$0.13, alongside trailing twelve month revenue of US$642.8 million and a TTM EPS loss of US$0.35 that keeps the focus squarely on the income statement. Over recent quarters the company has seen revenue range between US$149.0 million and US$172.9 million per quarter, with basic EPS swinging from a profit of US$0.28 in Q2 2025 to losses of US$0.28 in Q1, US$0.22...

Healthcare Services Group (HCSG) is back in focus after beating its own 2025 targets for revenue, earnings, and cash flow, wrapping up a $50 million buyback early and approving a fresh $75 million repurchase plan. See our latest analysis for Healthcare Services Group. The latest earnings beat, fresh 2026 guidance and new buyback plan appear to have reset expectations. A 24.44% year to date share price return and a 99.17% 1 year total shareholder return point to rebuilding momentum after...

What triggered the latest move in DraftKings (DKNG)? DraftKings (DKNG) reported fourth quarter 2025 results with US$1.99b in sales and US$136.43m in net income, and issued 2026 revenue guidance of US$6.5b to US$6.9b that disappointed the market. The stock sold off sharply after the release, as investors reacted to earnings per share that missed expectations and a revenue outlook that some viewed as signaling slower growth than previously hoped. See our latest analysis for DraftKings. At a...

Airbnb (NasdaqGS:ABNB) is rolling out its proprietary AI customer service agent globally after strong Q4 results. The AI system currently handles about one third of customer service issues in North America, with broader deployment planned. The company has hired Ahmad Al-Dahle, an AI specialist from Meta, as its new CTO to lead this AI-focused shift. Airbnb runs a global platform that connects guests with short term stays and experiences, and Q4 results have given the company fresh room to...

Why Proto Labs (PRLB) is Getting Fresh Attention Proto Labs (PRLB) is back on many investors’ screens after reporting record quarterly and annual revenue, coupled with improved profitability and a clear plan focused on long term growth and margin expansion. See our latest analysis for Proto Labs. That earnings beat and the plan to pursue selective acquisitions have gone hand in hand with strong momentum in the share price. A 30 day share price return of 25.81% and a 1 year total shareholder...

Cadence Design Systems (CDNS) has put AI at the center of its story with the launch of the ChipStack AI Super Agent, an agentic workflow that automates front end chip design and verification. See our latest analysis for Cadence Design Systems. The ChipStack AI Super Agent launch comes as Cadence Design Systems’ share price has seen mixed momentum, with a 1-day share price return of 3.86% and a 7-day return of 5.62%, set against a 30 day share price return of 4.38% and a year to date share...

Altruist has launched an AI powered tax planning tool that is drawing attention across the wealth management industry. The development has sparked debate about how artificial intelligence could affect traditional firms such as Charles Schwab, NYSE:SCHW. Investor reaction has been strong, with questions around potential fee pressure and shifts in client relationships. For Charles Schwab, NYSE:SCHW, the discussion arrives at a time when the stock has seen mixed recent performance. Shares...

Why Preferred Bank Stock Is Back on Investor Radar Preferred Bank (PFBC) has attracted fresh attention after quarterly earnings came in ahead of consensus expectations, paired with increased institutional interest, including a larger position from the New York State Common Retirement Fund. See our latest analysis for Preferred Bank. Despite the recent earnings beat and higher institutional ownership, Preferred Bank’s 1-month share price return of a 4.61% decline and year-to-date share price...

In early February 2026, APA Corporation’s board declared a regular cash dividend of US$0.25 per common share, payable on May 22, 2026, to shareholders of record as of April 22, 2026. This reaffirmed payout underlines APA’s continued emphasis on cash returns to investors even as analysts anticipate softer near-term earnings and revenue. We’ll now examine how this reaffirmed dividend fits into APA’s broader investment narrative, including cost discipline, capital returns, and upcoming...

Tempus AI recently announced a collaboration with Median Technologies to integrate Median’s FDA-cleared eyonis® LCS lung cancer screening software into the Tempus Pixel platform, enhancing AI-enabled analysis of CT images for lung nodule detection and risk stratification. This integration broadens Tempus AI’s radiology footprint by adding non-invasive malignancy scoring at the point of nodule detection, potentially making its precision medicine ecosystem more useful for clinicians running...

Caesars Entertainment (NasdaqGS:CZR) has announced a substantial renovation and expansion of the Flamingo Las Vegas, one of its flagship properties on the Strip. The company is also moving into the second phase of the transformation at Caesars Republic Lake Tahoe, further reshaping its resort footprint in that market. Both projects focus on upgrading guest experience and facilities at core assets in Caesars Entertainment’s hospitality and gaming portfolio. For investors, these projects...

Rambus (RMBS) is in the spotlight after a cluster of leadership updates, including the planned resignation of CFO Desmond Lynch, the appointment of interim CFO John Allen, reaffirmed guidance, and the addition of semiconductor veteran Victor Peng to its board. See our latest analysis for Rambus. The recent 6.42% 1 day share price return, taking Rambus to US$101.95, sits against a relatively modest 2.69% year to date share price return and a much stronger 61.93% total shareholder return over...

In recent days, Novavax drew fresh attention as investors reacted to softer-than-expected U.S. inflation data and growing interest in its protein-based vaccine platform as an alternative to mRNA technologies. This combination of macroeconomic optimism and focus on Novavax’s differentiated vaccine approach has highlighted the company’s role as a higher-risk, biotech underdog in a competitive vaccine landscape. Against this backdrop of easing inflation and renewed interest in its vaccine...

Darling Ingredients Inc. has reported fourth-quarter 2025 revenue of US$1,709.8 million, up from US$1,417.69 million a year earlier, while quarterly net income fell to US$56.94 million and full-year net income dropped to US$62.8 million despite higher annual sales of US$6,135.88 million. Behind these headline figures, the company delivered adjusted EBITDA above expectations with sequential gross margin improvement, suggesting its core ingredients operations helped offset weaker profitability...

In February 2026, CoreCivic reported Q4 2025 results showing revenue rising to US$603.95 million and net income to US$26.54 million, alongside full‑year 2025 net income of US$116.5 million and 2026 net income guidance of US$147.5 million to US$157.5 million with diluted EPS of US$1.49 to US$1.59. Management highlighted that revenue from Immigration and Customs Enforcement more than doubled year over year and that reactivating previously idle facilities, including new ICE-related contracts,...

Ferrari (NYSE:RACE) plans to unveil its first fully electric model, the Ferrari Luce, in May 2026. The company is adjusting its Formula 1 engineering structure ahead of Lewis Hamilton joining the team, including a new race engineer arrangement and search for a permanent hire. These moves highlight parallel shifts in Ferrari’s road-car and motorsport operations, with a focus on electrification and team reorganization. Ferrari sits at the high end of the luxury performance car market, with...

If you are wondering whether Bruker is starting to look like value after a rough stretch, this article will walk through what the current share price may or may not be offering you. The stock last closed at US$36.51, with returns of 12.9% decline over 7 days, 25.7% decline over 30 days, 24.1% decline year to date, 26.7% decline over 1 year, 49.9% decline over 3 years and 41.0% decline over 5 years. These moves sit against a backdrop of ongoing interest in Bruker as a life sciences tools and...

Innospec (IOSP) has come into focus after a research firm shifted its recommendation to buy and a company director added to their holdings, developments that may be shaping recent trading and investor interest. See our latest analysis for Innospec. Recent trading reflects a mixed picture, with the share price at US$86.58 after a 30 day share price return of 7.09% and a 90 day share price return of 16.86%. However, the 1 year total shareholder return is an 18.23% loss, suggesting that shorter...

Iovance Biotherapeutics (IOVA) recently reported real world data suggesting its commercial TIL therapy Amtagvi may have a best in class profile with strong response rates in advanced melanoma, which has refocused attention on the stock. See our latest analysis for Iovance Biotherapeutics. The real world Amtagvi data arrives after a volatile few years for shareholders. The recent 30 day share price return of 15.77% and a 1 day move of 1.98% at a US$2.57 share price stand in contrast to a 1...

Flowers Foods (FLO) just posted fourth quarter FY 2025 revenue of US$1.2b with a basic EPS loss of US$0.32, while trailing twelve month EPS came in at US$0.40 on revenue of US$5.3b. The company has seen quarterly revenue move from US$1.1b and EPS of US$0.20 in Q4 2024 to US$1.2b and EPS of US$0.19 in Q3 2025 before the latest quarterly loss, setting up a results season where investors are weighing weak reported profitability against forecasts for stronger earnings ahead. With net profit...

In the past week, Aramark reported first‑quarter fiscal 2026 results showing sales of US$4,831.55 million, higher than a year earlier, while net income and earnings per share from continuing operations were slightly lower; the company also completed a US$168.56 million buyback program and affirmed a quarterly dividend of US$0.12 per share. Management reiterated full‑year 2026 guidance, including expected revenue between US$19.55 billion and US$19.95 billion and mid‑single‑digit organic...